Fierce Biotech names Cellarity as one of its “Fierce 15” Biotech Companies of 2021

Section HeadingSection Content
Cambridge, MA – September 27, 2021

Cellarity today announced that Fierce Biotech has named it as one of 2021’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.

“In 2020, we got to celebrate the best and brightest biotechs trying to dig the world out of the pandemic. Speaking with this year’s class of Fierce 15 winners showed us that not even a global pandemic can stop incredible innovations in medicine, and we’re on the cusp of some new breakthrough treatments that have continued apace despite unprecedented disruption last year,” said Annalee Armstrong, Senior Editor of Fierce Biotech. “Slowing down was not an option for our 2021 Fierce 15 winners. From a biotech exploring a new type of viral vector for gene therapies to one trying to crack fibroblasts as a way to target resistant tumors, the Fierce Biotech team heard one thing in common: strong teams of scientists and professionals united in a goal to advance life-changing medicines. We’re proud to showcase this esteemed group of emerging biotechs to the world.”

Cellarity, a life sciences company founded by Flagship Pioneering to develop a new way to discover medicines by targeting the cell, has developed a unique combination of expertise across network biology, high-resolution data, and machine learning to unlock new treatment options in a vast array of disease areas.

“Disease occurs as a disorder at the cellular level. Despite this, historical efforts in drug discovery have taken a more reductionist approach and focused on single molecular targets, missing the complexity of changes that happen within a cell. Cellarity is driving an entirely new approach and creating a platform which can be applied to virtually any cell type and any disease,” said Fabrice Chouraqui, CEO of Cellarity and a CEO-Partner at Flagship Pioneering. “Using a combination of digital and biological models, we can look for cellular behaviors more broadly, more efficiently understand them, and then more effectively design new chemical entities that target them. We are thrilled to be included in this year’s Fierce 15 alongside other visionary companies united in reversing the course of disease to bring breakthrough medicines to patients.”

The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is Fierce Biotech’s 19th annual Fierce 15 selection.

An internationally recognized daily report reaching a network of over 300,000 biotech and pharma industry professionals, Fierce Biotech provides subscribers with an authoritative analysis of the day’s top stories. Every year Fierce Biotech evaluates hundreds of early-stage companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

About Cellarity

Cellarity’s mission is to bring breakthrough medicines to patients by completely redefining the way drugs are discovered. Founded by Flagship Pioneering in 2017, Cellarity is designing medicines against the cell as opposed to a single molecular target. The company has developed a unique combination of expertise across network biology, high-resolution data, and machine learning to unlock new treatment options in a vast array of disease areas. Cellarity currently has drug discovery programs underway in metabolic disease, hematology, immuno-oncology and respiratory disease. The company has raised $123 million as part of a Series B funding round with contributions from funds and accounts managed by Blackrock, The Baupost Group, Banque Pictet on behalf of their clients, and eight other investors alongside Flagship Pioneering.

About Fierce Biotech

Fierce Biotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 300,000 top biopharma professionals rely on Fierce Biotech for an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com/signup.

Contacts

Annie Lydgate
Cellarity
617-417-4196
press@cellarity.com

Rebecca Willumson
Fierce Biotech
202-824-5050

rwillumson@questex.com

Up Next

Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases